Bivalent mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease

Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1074-1075. doi: 10.1016/S2468-1253(23)00310-2. Epub 2023 Oct 6.

Authors

Joshua Quan¹, Ante Markovinović¹, Lindsay Hracs¹, Christopher Ma¹, Remo Panaccione¹, Gilaad G Kaplan²; STOP COVID-19 in IBD Research Group

Collaborators

Affiliations

¹ Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, AB T2N 4Z6, Canada.
² Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, AB T2N 4Z6, Canada. Electronic address: ggkaplan@ucalgary.ca.

PMID: 37813111
DOI: 10.1016/S2468-1253(23)00310-2

No abstract available

Publication types

Letter

MeSH terms

COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Inflammatory Bowel Diseases*
SARS-CoV-2

Substances

COVID-19 Vaccines